- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Allogene Therapeutics, Inc. The post 8-K: Report of unscheduled material events or corporate event appeared first on Allogene.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive The post Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker appeared first on Allogene.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the The post Allogene Therapeutics Announces Participation in September Investor Conference appeared first on Allogene.
Allogene Therapeutics, Inc. The post 4: Statement of changes in beneficial ownership of securities appeared first on Allogene.
Allogene Therapeutics, Inc. The post 144: Filed by “insiders” prior intended sale of restricted stock. appeared first on Allogene.
Allogene Therapeutics, Inc. The post EFFECT: EFFECT appeared first on Allogene.
Allogene Therapeutics, Inc. The post SCHEDULE 13G/A: SCHEDULE 13G/A – Description appeared first on Allogene.
Allogene Therapeutics, Inc. The post S-3: Simplified registration form appeared first on Allogene.
Allogene Therapeutics, Inc. The post 10-Q: Quarterly report which provides a continuing view of a company’s financial position appeared first on Allogene.
Allogene Therapeutics, Inc. The post 8-K: Report of unscheduled material events or corporate event appeared first on Allogene.